Thomas Zimmermann

Thomas Zimmermann

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2022 in RSC Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
PSPhilipp Spatz
Philipp Spatz
TZThomas Zimmermann
Thomas Zimmermann
SSSophie Steinmüller
Sophie Steinmüller
JHJulian Hofmann
Julian Hofmann
TMTangui Maurice
Tangui Maurice
MDMichael Decker
Michael Decker
Benzimidazole-based inhibitors of butyrylcholinesterase were designed and tested for their activity and selectivity in vitro , leading to compound (11d) that attenuated Aβ 25-35 -induced learning impairments in an Alzheimer's disease mouse model.

17 February 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ATAnna Tutov
Anna Tutov
XCXinyu Chen
Xinyu Chen
RWRudolf A. Werner
Rudolf A. Werner
SMSaskia Mühlig
Saskia Mühlig
TZThomas Zimmermann
Thomas Zimmermann
THTakahiro Higuchi
Takahiro Higuchi
Purpose: A new PET radiotracer 18F-AF78 showing great potential for clinical application has been reported recently. It belongs to a new generation of phenethylguanidine-based norepinephrine transporter (NET)-targeting radiotracers. Although many efforts have been made to develop NET inhibitors as antidepressants, systemic investigations of the structure–activity relationships (SARs) of NET-targeting radiotracers have rarely been performed. Methods: Without changing the phenethylguanidine pharmacophore and 3-fluoropropyl moiety that is crucial for easy labeling, six new analogs of 18F-AF78 with different meta-substituents on the benzene-ring were synthesized and evaluated in a competitive cellular uptake assay and in in vivo animal experiments in rats. Computational modeling of these tracers was established to quantitatively rationalize the interaction between the radiotracers and NET. Results: Using non-radiolabeled reference compounds, a competitive cellular uptake assay showed a decrease in NET-transporting affinity from meta-fluorine to iodine (0.42 and 6.51 µM, respectively), with meta-OH being the least active (22.67 µM). Furthermore, in vivo animal studies with radioisotopes showed that heart-to-blood ratios agreed with the cellular experiments, with AF78(F) exhibiting the highest cardiac uptake. This result correlates positively with the electronegativity rather than the atomic radius of the meta-substituent. Computational modeling studies revealed a crucial influence of halogen substituents on the radiotracer–NET interaction, whereby a T-shaped π–π stacking interaction between the benzene-ring of the tracer and the amino acid residues surrounding the NET binding site made major contributions to the different affinities, in accordance with the pharmacological data. Conclusion: The SARs were characterized by in vitro and in vivo evaluation, and computational modeling quantitatively rationalized the interaction between radiotracers and the NET binding site. These findings pave the way for further evaluation in different species and underline the potential of AF78(F) for clinical application, e.g., cardiac innervation imaging or molecular imaging of neuroendocrine tumors.